180 related articles for article (PubMed ID: 37915584)
21. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.
van de Logt AE; Dahan K; Rousseau A; van der Molen R; Debiec H; Ronco P; Wetzels J
Kidney Int; 2018 Apr; 93(4):1016-1017. PubMed ID: 29571438
[No Abstract] [Full Text] [Related]
22. Combination of Rituximab and Low-dose Tacrolimus in the Treatment of Refractory Membranous Nephropathy: A Retrospective Cohort Study.
Chen X; Jiao S; Li S; Li J; Li P; Song F; Yan Z
Balkan Med J; 2023 Jul; 40(4):287-293. PubMed ID: 37260416
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy.
Zou H; Jiang F; Xu G
Ren Fail; 2019 Nov; 41(1):673-681. PubMed ID: 31354007
[No Abstract] [Full Text] [Related]
24. Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience.
Chen P; Mao M; Wang C; Zhang X; Zhao X; Gao Y; Luo Y; Zhou Y
Front Endocrinol (Lausanne); 2023; 14():1044782. PubMed ID: 36875477
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of long-term repeated rituximab treatment in refractory phospholipase A2 receptor-antibody-related membranous nephropathy.
Zhang L; Chen M; Le W; Zhang M; Tu Y; Zuo K; Chen D; Wu Y; Li S; Zeng C; Cheng Z; Xie H
Immunotherapy; 2022 Oct; 14(15):1237-1244. PubMed ID: 36097696
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment of PLA
Schmidt T; Schulze M; Harendza S; Hoxha E
J Nephrol; 2021 Apr; 34(2):603-606. PubMed ID: 33026632
[TBL] [Abstract][Full Text] [Related]
27. The Efficacy of Rituximab in the Treatment of Membranous Nephropathy.
Maharjan R; Wang JW; Shrestha IK
J Nepal Health Res Counc; 2021 Jan; 18(4):580-587. PubMed ID: 33510493
[TBL] [Abstract][Full Text] [Related]
28. Rituximab for the treatment of membranous nephropathy: a single-center experience.
Aleš Rigler A; Jerman A; Orsag A; Kojc N; Kovač D; Škoberne A; Borštnar Š; Večerić Haler Ž; Avguštin N; Kveder R; Ferluga D; Vizjak A; Lindič J
Clin Nephrol; 2017 Supplement 1; 88(13):27-31. PubMed ID: 28664837
[TBL] [Abstract][Full Text] [Related]
29. Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial.
Nikolopoulou A; Condon M; Turner-Stokes T; Cook HT; Duncan N; Galliford JW; Levy JB; Lightstone L; Pusey CD; Roufosse C; Cairns TD; Griffith ME
BMC Nephrol; 2019 Sep; 20(1):352. PubMed ID: 31492152
[TBL] [Abstract][Full Text] [Related]
30. Detection and clinical significance of glomerular M-type phospholipase A
Liu H; Luo W; Gong S; Ding X
Intern Med J; 2016 Nov; 46(11):1318-1322. PubMed ID: 27554390
[TBL] [Abstract][Full Text] [Related]
31. The STARMEN trial: rethinking calcineurin inhibitor therapy in membranous nephropathy.
Floege J; Rovin BH
Kidney Int; 2021 Apr; 99(4):811-813. PubMed ID: 33745547
[TBL] [Abstract][Full Text] [Related]
32. Profile and primary treatment outcomes in membranous nephropathy.
Hemanth Kumar MK; Sandhu J; Sandhu JS
Saudi Med J; 2022 Sep; 43(9):1051-1056. PubMed ID: 36104046
[TBL] [Abstract][Full Text] [Related]
33. Membranous Nephropathy: It Is Time to Go Back to the Future.
Sabiu G; Podestà MA
Nephron; 2021; 145(6):721-727. PubMed ID: 34225270
[TBL] [Abstract][Full Text] [Related]
34. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
[TBL] [Abstract][Full Text] [Related]
35. Novel treatment options in rituximab-resistant membranous nephropathy patients.
Ahmadian E; Khatibi SMH; Vahed SZ; Ardalan M
Int Immunopharmacol; 2022 Jun; 107():108635. PubMed ID: 35240381
[TBL] [Abstract][Full Text] [Related]
36. [A novel approach to rapid induction of remission in primary membranous nephropathy].
Dobronravov VA; Bystrova OB; Kochoyan ZS; Fomicheva EN
Ter Arkh; 2021 Jun; 93(6):706-712. PubMed ID: 36286838
[TBL] [Abstract][Full Text] [Related]
37. Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New-incident and relapsing primary membranous nephropathy.
Kanigicherla DAK; Hamilton P; Czapla K; Brenchley PE
Nephrology (Carlton); 2018 Jan; 23(1):60-68. PubMed ID: 27778424
[TBL] [Abstract][Full Text] [Related]
38. Treatment of membranous nephropathy with crescent nephritis by rituximab: A case report.
Zhang F; Yang Y; Chen Y; Chen Y; Yin W; Liang Y; Luo X
Medicine (Baltimore); 2022 Sep; 101(37):e30663. PubMed ID: 36123923
[TBL] [Abstract][Full Text] [Related]
39. Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy.
Delafosse M; Ponlot E; Esteve E; Ghislain L; Hanset N; Boffa JJ; Johanet C; Dahan K
Kidney Int; 2021 Apr; 99(4):1023-1024. PubMed ID: 33745532
[No Abstract] [Full Text] [Related]
40. Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial.
Scolari F; Dallera N; Gesualdo L; Santoro D; Pani A; Santostefano M; Feriozzi S; Mani LY; Boscutti G; Messa P; Magistroni R; Quaglia M; Ponticelli C; Ravani P
BMJ Open; 2019 Dec; 9(12):e029232. PubMed ID: 31806605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
